Quest Diagnostics Launches Advanced Pharmacogenomic Testing Service for Healthcare Providers

Strategic Insights -

Quest Diagnostics has announced the launch of an advanced pharmacogenomic (PGx) laboratory test service designed to help healthcare providers understand a patient's individual genetic response to select drug therapies. This innovative offering aims to inform medication selection and dosing across various medical specialties, including psychiatry, neurology, cardiology, oncology, rheumatology, pain management, and transplant recipient care.

Key Takeaways:

  • Quest Diagnostics has introduced a pharmacogenomic (PGx) laboratory test service to help healthcare providers understand a patient's genetic response to select drug therapies.
  • The service utilizes PGx information across 17 genes and 4 HLA alleles, encompassing genes with recognized evidence of gene-drug associations and defined medical utility.
  • The PGx offering includes a Quest-delivered report with genotype (diplotye) and predicted phenotypic response, alongside vital medication guidance powered by Coriell Life Sciences (now InformedDNA).
  • Clinicians have direct access to GeneDose LIVE, a clinical decision support tool for comprehensive evaluation of the patient's therapeutic regimen.
  • Quest is also offering an alternative option with just the genotype and predicted phenotypic response.
  • Patients can access the test through a requisition (test order) from their doctor at one of Quest's 2,000 patient service centers across the United States, or through at-home phlebotomy collection.
  • Research suggests that PGx testing may have great potential to prevent therapeutic failure and Adverse Drug Interactions (ADIs), and can help avoid unnecessary drug costs and management of drug-related complications.

Statistics:

  • Quest Diagnostics offers the PGx test service across 17 genes and 4 HLA alleles.
  • The service includes a comprehensive report with genotype (diplotye) and predicted phenotypic response, alongside vital medication guidance.
  • Patients' genetic data is translated into clear guidance on which medications are most likely to be effective for each patient through InformedDNA's reporting.
  • Quest operates 2,000 patient service centers across the United States, facilitating patient access to the PGx test service.
  • Home collection services are also available through Quest's at-home phlebotomy collection.

Sources:

  • Quest Diagnostics (NewsRx)